ARTreat

ARTreat targets at providing a patient-specific computational model of the cardiovascular system, used to improve the quality of prediction for the atherosclerosis progression and propagation into life-threatening events that need to be treated accordingly.

ARTreat will provide a three-level patient model describing the 3d arterial tree anatomy, the patient-specific blood flow and blood particle dynamics and the biological processes that lead to the creation and progression of atherosclerotic plaques.

ARTreat will apply the developed patient-specific model on two main applications: the clinical decision support and the training. ARTreat will produce two decision support tools to assist clinical cardiologists into providing personalized treatment selection and real-time, on- the-fly advice during invasive interventions, such stent positioning. The aim is to minimize future therapy costs, by providing higher than even possible personalized treatment support. The same patient-specific model will also be used to develop a real-case simulator training, which will support realistic hands-on skill development training to clinical cardiologists.

Finally, ARTreat is coupled with advanced clinical support tools for plaque characterization, and the discovery of new knowledge; associations among heterogeneous data, that can improve the predictive power of the patient-model. It thus supports the medical expert into programming the accumulated knowledge into the existing model and generating an adaptive patient-specific computational tool. Key market players AGFA and SORIN will exploit the ARTreat applications to provide new sophisticated solutions to their product range, while all academic and IT company partners will accumulate significant experience on the new generation patient-specific healthcare services.

For further information, please visit:
http://www.artreat.org

Project co-ordinator:
SWORD TECHNOLOGIES SA

Partners:

  • UNIVERZITET U KRAGUJEVCU
  • COMPUTER SHARING BUCURESTI SRL
  • TECHNOLOGICA EOOD
  • SAS SOFTWARE LIMITED
  • LANZA & THOMPSON INFORMATION TECHNOLOGY SRL
  • TECMIC-TECNOLOGIAS DE MICROELECTRONICA SA
  • FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
  • ADVANCED SIMULATION AND DESIGN GMBH
  • UNIVERSITE PARIS DESCARTES
  • INTERCON SP. Z O.O.
  • EURO (PMS) LIMITED
  • SORIN BIOMEDICA CARDIO S.R.L.
  • AGFA HEALTHCARE N.V.
  • WORLD MATCH LIMITED
  • D.D. SYNERGY HELLAS ANONYMI EMPORIKI ETAIREIA PAROCHIS YPIRESION PLIROFORIKIS
  • CONSIGLIO NAZIONALE DELLE RICERCHE
  • UNIVERSITA DEGLI STUDI DI PARMA

Timetable: from 09/2008 –to 08/2011

Total cost: 10.520.000

EC funding: €7.650.000

Programme Acronym: FP7-ICT

Subprogramme Area: ICT-2007.5.3 Virtual physiological human

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...

Siemens Healthineers Introduces Symbia P…

Siemens Healthineers introduces Symbia Pro.specta™, a single-photon emission computed tomography/computed tomography (SPECT/CT) system with CE Mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging...